Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
- 1 May 2014
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 2 (5), 393-398
- https://doi.org/10.1158/2326-6066.cir-14-0039
Abstract
The cancer immunotherapy field has grown exponentially in the past few years, largely driven by the success of immune checkpoint blockade. Therapies targeting the immune checkpoint molecules CTLA-4 and PD-1 have achieved objective responses in melanoma, renal cancer, and lung cancer; however, a large number of patients are still suffering with these cancers that are not benefiting from these therapies. Moreover, several cancers have proved to be largely refractory to therapies that target CTLA-4 and PD-1. This has catalyzed interest in targeting novel immune checkpoint receptors with the goal of realizing the full potential of checkpoint blockade for treating cancer. In this regard, the immune checkpoint receptor Tim-3 exhibits several unique features that make it an intriguing candidate for the next wave of therapies that target immune checkpoints in cancer. Cancer Immunol Res; 2(5); 393–8. ©2014 AACR.Keywords
This publication has 35 references indexed in Scilit:
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nature Immunology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cellsNature, 2012
- Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell markerProceedings of the National Academy of Sciences of the United States of America, 2011
- Four faces of cellular senescenceThe Journal of cell biology, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityThe Journal of Experimental Medicine, 2010
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patientsThe Journal of Experimental Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infectionProceedings of the National Academy of Sciences of the United States of America, 2010
- Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infectionThe Journal of Experimental Medicine, 2008